Biopool International's thrombosis risk test:
This article was originally published in Clinica
The US FDA has cleared Biopool International's Bioclot aPC sensitivity kit designed to detect an individual's resistance to activated protein C. This resistance indicates a mutation in the clotting factor V gene which in turn signals the individual's risk of developing a thrombotic disease.
You may also be interested in...
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
In second letter this year targeting email communications, OPDP says that putting the methotrexate oral solution’s risk information below the signature block does not offer ‘prominence and readability’ comparable to the information on the drug’s effectiveness for the treatment of acute lymphoblastic leukemia that was in the body of the email.